作者：杨淑莲，吴晓羽

单位：

关键词：

沙库巴曲缬沙坦；血管紧张素受体脑啡肽酶抑制剂；心力衰竭；高血压；心肌梗死；糖尿病；心脏代谢综合征；肾功能不全

Keywords：

Sacubitril/valsartan；Angiotensin receptor enkephalinase inhibitor；Heart failure；Hypertension；Myocardial infarction；Diabetes mellitus；Cardiometabolic syndrome；Renal insufficiency

CLC：

R 917

DOI：

DOI：10.3969/j.issn.1008-5971.2020.05.016

Funds：

摘要：

沙库巴曲缬沙坦即血管紧张素受体脑啡肽酶抑制剂（ARNI），是近年来心力衰竭领域的研究热点。多项研究显示该药可明显降低心力衰竭患者的住院率和死亡率，并对多种心血管疾病有良好获益。本文简述了沙库巴曲缬沙坦在心力衰竭、高血压、急性心肌梗死、糖尿病、心脏代谢综合征和肾功能不全等疾病中的相关研究进展，进一步表明沙库巴曲缬沙坦现已不仅局限于射血分数降低的心力衰竭的临床应用，而是对多种心血管疾病甚至非心血管疾病均有潜在的有益作用。

Abstract：

Sacubitril/valsartan is angiotensin receptor enkephalinase inhibitor（ARNI）and is a research hotspotin the field of heart failure in recent years.Multiple studies have found that sacubitril/valsartan can significantly reduce thehospitalization rate and mortality of patients with heart failure，and have good benefits for a variety of cardiovascular diseases.This article briefly describes the related research progress on the effects of sacubitril/valsartan in heart failure，hypertension，acute myocardial infarction，diabetes，cardiometabolic syndrome and renal insufficiency.It further shows that sacubitril/valsartanis not limited to the clinical application of heart failure with reduced ejection fraction，but has potential beneficial effects onvarious cardiovascular diseases and even non-cardiovascular diseases.

ReferenceList：